TORONTO, Oct. 22 /CNW/ -- Ranbaxy Pharmaceuticals Canada Inc. (RPCI), a
wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today
that RLL has received approval in Canada to manufacture and market
RAN(R)-Lisinopril 5, 10 and 20 mg oral tablets from Health Canada, Therapeutic
Products Directorate (TPD). Total brand market for Lisinopril 5, 10, and 20
mg oral tablets in Canada is CAD $46 mil. (IMS-MAT: August 2007).
